Alison Stopeck, MD

Associate Professor of Medicine

Director, Clinical Breast Cancer Program, AZCC

Director, AZ Hemophilia and Thrombosis Center

E-Mail Address: 
astopeck@azcc.arizona.edu
Phone Number: 
(520) 626-2816
Fax: 
(520) 626-3754
Short Bio: 

Alison Stopeck is a board certified Internist, Hematologist, and Medical Oncologist and Director of the Arizona Hemophilia and Thrombosis Center-Tucson and the Clinical Breast Cancer Program at the The University of Arizona Cancer Center . She received her medical doctorate from Columbia University College of Physicians and Surgeons. She then remained at Columbia, completing her residency in Internal Medicine at Columbia Presbyterian Medical Center. Her Fellowship in Hematology and Oncology was completed at Cornell University Medical College.

She currently holds the rank of Associate Professor of Medicine at the University of Arizona. She has more than 50 publications in medical journals and textbooks, including the New England Journal of Medicine and the Journal of Clinical Oncology. She acts as an Associate Editor for the American Journal of Medicine and is an ad hoc reviewer for several journals. Memberships include the American Society of Clinical Oncology, the American Society of Hematology, the American Association of Cancer Research, and the Southwest Oncology Group. She has been named to the “Best Doctors in America”, “Best Doctors in Tucson”, and “Who’s Who in America, Professional Edition” on multiple occasions and has a very active clinical practice in breast cancer as well as bleeding and clotting disorders. Dr. Stopeck is the principle or collaborating investigator on multiple clinical trials involving novel agents, prognostic markers and predictors of response in breast cancer patients, as well as supportive care and survivorship issues in hemophilia and breast cancer.

Clinical Information
Specialty: 
Medical Oncologist
Clinical Practice Sites: 
The University of Arizona Cancer Center - North Campus
Research Information
Research Program: 
1. Therapeutic Development
Member Status: 
Member
Year of Membership Acceptance: 
1994
Institution: 
University of Arizona
College: 
University of Arizona
Selected Publications: 

Refereed Journal Articles:

AT Stopeck, A Lipton, JJ Body, GG Steger, K Tonkin, R de Boer, M Lichinitser, Y Fujiwara, D Yardley, M Viniegra, M Fan, Q Jiang, A Braun, R Dansey, S Jun. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010 Dec 10; 28:5132-9.

Chalasani P, Downey L, Stopeck AT. Caring for the breast cancer survivor: a guide for primary care physicians. Am J Med 2010 June;123(6):489-95

Brown-Glaberman U, Graham A, Stopeck A. A case of metaplastic carcinoma of  the breast responsive to chemotherapy with Ifosfamide and Etoposide: improved antitumor response by targeting sarcomatous features. Breast J. 2010 Nov-Dec;16(6):663-5. doi: 10.1111/j.1524-4741.2010.00975.x. No abstract available. PMID: 21070449 [PubMed]

Gordon MS, Mendelson D, Carr R, Knight RA, Humerickhouse RA, Iannone M, Stopeck AT.  A phase I trial of 2 dose schedules f ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer. 2008 Dec 15;113(12):3420-9

Downey L, Livingston R, Stopeck AT. Diagnosing and treating breast cancer in elderly women: a call for improved understanding. J Am Geriatrics Society, 55:1636-44, 2007.

Modi S, Stopeck AT, Gordon MS, Mendelson D , Solit D,  Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG,  Hannah AL, Hudis CA. Combination of trastuzumab and tanespimycin (17 AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol., 25:5410-7, 2007.

Hayes DF,Cristofanilli M, Budd GT, Ellis MJ, Stopeck AT, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 15;12 (14 PT 1):4218-4224 July, 2006

Budd GBudd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF.Circulating Tumor Cells versus Imaging-Predicting Overall survival in Metastatic Breast Cancer. Clinical Cancer Research, 12:6403-9, 2006

Brown-Glaberman U, Swart R, Dragovich T, Bracamonte E, Kurtin,S, Stopeck A. Hepatic injury associated with bevacizumab use in metastatic breast and colon cancers: a review of two cases. Community Oncology Vol 5, No 10 (2008 Oct):pp539-42

Swart R, Stopeck A, Next Generation of Targeted Therapies in Breast Cancer. Biological therapy of BreBreast Cancer. November 2008, Vol 9, no 2.

Thomson CA, Stopeck AT, Bea JW, Cussler E, Nardi E, Frey G, Thompson PA. Changes in body weight and metabolic indexes in overweight breast cancer survivors enrolled in a randomized trial of low-fat vs. reduced carbohydrate diets. Nutr Cancer. 2010 Nov;62(8):1142-52.PMID: 21058203 [PubMed - in process]Related citations

Thomson CA, Thompson PA, Wright-Bea J, Nardi E, Frey GR, Stopeck A., Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapy. J Women’s Health. 2009 Dec. 18: 2041-7

Gerstner G, Damiano ML, Tom A, Worman C, Schultz W, Recht M, Stopeck AT. Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia, 2009 Mar, 15(2):559-65.

U Brown-Glaberman, M Cordoba Kissee, ML Damiano, DJ Roe, AT Stopeck. Decreased bone mineral density in Patients with Hemophilia: Review of the Literature. Journal of Coagulation Disorders. 2010 (in press).

Chapters in Scholarly Books and Monographs:

Thompson PA, Stopeck AT. Breast Cancer Prevention. In:Fundamentals of Cancer Prevention, Alberts DS and Hess LM (eds), Springer. Verlad, Heidelberg, 2008 (second edition)

Swart R, Downey L, Lang J, Thompson P, Livingston R, Stopeck A. Breast Cancer. eMedicine from WebMD. Updated July 30, 2009.

 

Professional Information
Board Certifications: 

American Board of Internal Medicine

Hematology Subspecialty Board

Oncology subspecialty Board

Professional Affiliations: 

American Society of Clinical Oncology
American Association for Cancer Research
Southwest Oncology Group
Hemophilia Thrombosis Research Society
World Federation of Hemophilia

Honors: 

Who's Who in America-Professonial Edition

Best Doctors in America, Woodard/White, Inc.

Best Doctors in Tucson, Tucson Lifestyle Magazine

America's Top Doctor for Cancer

Academic Information
Fellowship: 
Cornell University Medical College
Residency: 
Columbia Presbyterian Medical Center
Medical School: 
Columbia University College of Physicians and Surgeons